Results 41 to 50 of about 12,647 (196)

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations [PDF]

, 2013
Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are ...
Alberti, M., Bresin, E., Galbusera, M., Noris, M., Piras, R., Remuzzi, G., Thaiss, F., TRIPODO, Claudio, Valoti, E.   +8 more
core   +1 more source

Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome

Saudi Journal of Kidney Diseases and Transplantation, 2017
Atypical hemolytic-uremic syndrome is a disease characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal failure. In this study, we present a case of a patient with atypical hemolytic-uremic syndrome treated successfully with eculizumab ...
Funda Sari, Ayça Inci, Volkan Karakus, Banu Yilmaz, Metin Sarikaya, Refik Olmaz, Erdal Kurtoglu   +6 more
doaj   +1 more source

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report [PDF]

, 2015
INTRODUCTION: Thrombotic microangiopathies are a group of diseases presenting as microangiopathic hemolytic anemia, thrombocytopenia and end-organ dysfunction.
Abdulkadir Unsal, Cuneyt Akgol, David Kavanagh, Ekrem Kara, Elbis Ahbap, Mustafa Sevinc, Tamer Sakaci, Taner Basturk, Tim HJ Goodship, Tuncay Sahutoglu, Vicky Brocklebank, Yener Koc   +11 more
core   +1 more source

Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report

BMC Nephrology, 2019
Background Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury.
Subagini Nagarajah, Martin Tepel, Christian Nielsen, Kristian Assing, Yaseelan Palarasah, Lise Lotte Torvin Andersen, Lotte Borg Lange, Claus Bistrup   +7 more
doaj   +1 more source

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Romanian Journal of Internal Medicine, 2022
Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of ...
Yeter Hasan H., Derici Ulver, Arinsoy Turgay, Altok Kadriye, Erten Yasemin, Guz Galip   +5 more
doaj   +1 more source

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. [PDF]

, 2014
BackgroundAtypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized ...
A Szilagyi, Aspazija Sofijanova, Attila Szabó, C Loirat, CM Legendre, D Kavanagh, D Magen, F Fakhouri, F Fakhouri, G Ariceta, G Ariceta, György Reusz, J Caprioli, J Zuber, J Zuber, JM Campistol, Klaus Arbeiter, Krisztina Rusai, Lilla Szeifert, LM Geerdink, M Christmann, M Heurich, M Jozsi, M Lemaire, M Reti, MA Abrera-Abeleda, MA Dragon-Durey, Miklós Szabó, N Besbas, Nóra Szarvas, RA Gruppo, RL Ruebner, S Jung, Thomas Müller, Valbona Nushi-Stavileci, Velibor Tasic, Z Prohaszka, Zoltán Prohászka, Zoran Gucev, Ágnes Szilágyi   +39 more
core   +1 more source

Pathogenesis of Atypical Hemolytic Uremic Syndrome

Journal of Atherosclerosis and Thrombosis, 2019
Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure. aHUS is caused by uncontrolled complement activation in the alternative pathway (AP).
Yoshida, Yoko, Kato, Hideki, Ikeda, Yoichiro, Nangaku, Masaomi   +3 more
openaire   +3 more sources

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael, Parikh, MD, Kinjal   +1 more
core   +2 more sources

Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology

Brazilian Journal of Nephrology, 2018
Scleroderma is an autoimmune disease that affects multiple systems. While pathophysiologic mechanisms governing the development of scleroderma are relatively poorly understood, advances in our understanding of the complement system are clarifying the ...
Roman Zuckerman, Arif Asif, Eric J. Costanzo, Tushar Vachharajani   +3 more
doaj   +1 more source

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizimab treatment [PDF]

, 2016
Background: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and ...
Ardissimo, Gianluigi, Delmas, Yahsou, Haller, Herman, Kincaid, John F, Vande Walle, Johan, Wang, Jimmy   +5 more
core   +2 more sources